# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k121994   
B. Purpose for Submission: New device   
C. Measurand: Vitamin B12   
D. Type of Test: Quantitative chemiluminescent immunoassay based on LOCI $\textsuperscript { \textregistered }$ technology   
E. Applicant: Siemens Healthcare Diagnostics   
F. Proprietary and Established Names: Dimension Vista $\textsuperscript { \textregistered }$ LOCI Vitamin B12 Flex $\textsuperscript { \textregistered }$ reagent cartridge and Dimension Vista $\textsuperscript { \textregistered }$ LOCI 4 Calibrator (LOCI 4 CAL)

G. Regulatory Information:

<table><tr><td>Product Code</td><td>Classification</td><td>Regulation Section</td><td>Panel</td></tr><tr><td>CDD</td><td>I</td><td>21 CFR 862.1810, Vitamin B12 Test System</td><td>Chemistry (75)</td></tr><tr><td>JIX</td><td>I</td><td>21 CFR 862.1150, Calibrator</td><td>Chemistry (75)</td></tr></table>

# H. Intended Use:

1. Intended use(s): See Indications for use below.

2. Indication(s) for use:

The VB12 method is an in vitro diagnostic test for the quantitative measurement of vitamin B12 in human serum and plasma on the Dimension Vista $\textsuperscript { \textregistered }$ System. Measurements of vitamin B12 are used in the diagnosis and treatment of anemias of gastrointestinal malabsorption.

The LOCI 4 CAL is an in vitro diagnostic product for the calibration of LOCI Ferritin (FERR), LOCI Folate (FOL), and LOCI Vitamin B12 (VB 12) methods on the Dimension Vista $\textsuperscript { \textregistered }$ System.

3. Special conditions for use statement(s): For prescription use only   
4. Special instrument requirements: Dimension Vista $\textsuperscript { \textregistered }$ 1500 System

# I. Device Description:

Dimension Vista $\textsuperscript { \textregistered }$ LOCI Vitamin B12 Flex $\textsuperscript { \textregistered }$ reagent cartridge:

· Wells 1 $- 2 \colon 3 6 0 ~ \mu \mathrm { g / m L }$ Liquid VB12 Sensibead reagent   
· Wells 3-4: 0.75N Sodium Hydrocide and 3mM Potassium Cyanide   
· Wells $5 { - } 6 \colon 1 0 \mathrm { m g / m L }$ Dithioerythriol tablet   
· Wells 9-10: $2 0 0 ~ \mu \mathrm { g / m L }$ VB12 Chemibead reagent   
· Wells 11-12: $3 ~ \mathrm { n g / m L }$ Biotinylated IF and $6 0 ~ \mathrm { n g / m L }$ Dicyanocobinamide

Dimension Vista $\textsuperscript { \textregistered }$ LOCI 4 Calibrator:

10 Vials $( 2 . 0 \mathrm { m L }$ each) of Dimension Vista $\textsuperscript { \textregistered }$ LOCI 4 Calibrator. The LOCI 4 Calibrator is a liquid multi-analyte product containing Ferritin from human liver, Folate, and Vitamin B12 in HEP ES buffer matrix (CAL A) or a bovine serum albumin Matrix (CAL B-E). Calibrators have the following approximate target concentrations:

<table><tr><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>Vit B12(pg/mL)Folate (ng/mL)</td><td rowspan=1 colspan=1>Vit B12(pg/mL)Folate (ng/mL)</td><td rowspan=1 colspan=1>Ferritin (ng/mL)</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>25</td></tr><tr><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>210</td></tr><tr><td rowspan=1 colspan=1>D</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>1050</td></tr><tr><td rowspan=1 colspan=1>E</td><td rowspan=1 colspan=1>2200</td><td rowspan=1 colspan=1>21.0</td><td rowspan=1 colspan=1>2200</td></tr></table>

The human albumin donor units used in the Dimension Vista $\textsuperscript { \textregistered }$ LOCI 4 Calibrator were tested with FDA approved assays and found to be nonreactive for ${ \mathrm { H B s A g } } .$ , HIV-1 RNA or HIV-1 Ag, anti-HIV-1/HIV-2, and anti-HCV.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Roche Elecsys Vitamin B12 Immunoassay

2. Predicate K number(s):

k060755

3. Comparison with predicate:

Reagent

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Proposed DeviceDimension Vista VB12</td><td rowspan=1 colspan=1>Predicate DeviceRoche Elecsys VB12(k060755)</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>In vitro diagnostic test forthe quantitativemeasurement of vitaminB12 in human serum andplasma</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Proposed Device</td><td rowspan=1 colspan=1>Predicate Device (k060755)</td></tr><tr><td rowspan=1 colspan=1>Platform</td><td rowspan=1 colspan=1>The Dimension VistaVitamin B12 method (V12)is for use on the DimensionVista System</td><td rowspan=1 colspan=1>The Roche Vitamin B12Assay is for use on Elecsys2010 and cobas eimmunoassay analyzers</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Chemiluminescence</td><td rowspan=1 colspan=1>Electrochemiluminescence</td></tr><tr><td rowspan=1 colspan=1>Measuring range</td><td rowspan=1 colspan=1>60 - 2000 pg/mL</td><td rowspan=1 colspan=1>30 - 2000 pg/mL</td></tr><tr><td rowspan=1 colspan=1>Sample Size</td><td rowspan=1 colspan=1>12 μL</td><td rowspan=1 colspan=1>15 μL</td></tr></table>

Calibrator:

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Proposed DeviceModified LOCI 4 CAL</td><td colspan="1" rowspan="1">Predicate DeviceLOCI 4 CAL (k071224)</td></tr><tr><td colspan="1" rowspan="1">Intended Use/IndicationsFor use</td><td colspan="1" rowspan="1">The LOCI 4 CAL is an invitro diagnostic product forthe calibration of the LOCIFerritin, LOCI Folate, andLOCI Vitamin B12methods on the DimensionVista System</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Traceability</td><td colspan="1" rowspan="1">Ferritin: WHO Standard forFerritin, 3rd IS 94/572</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Folate: United StatesPharmacopeia Grade FolicAcidVB12: United StatesPharmacopeia Grade VB12</td><td colspan="1" rowspan="1"></td></tr></table>

<table><tr><td colspan="3">Differences</td></tr><tr><td>Item</td><td>Proposed Device Modified LOCI 4 CAL</td><td>Predicate Device LOCI 4 CAL (k071224)</td></tr><tr><td>Matrix</td><td>HEPES Buffer Level A 2% BSA based matrix Level B-E</td><td>6% BSA based matrix Level A-E</td></tr><tr><td rowspan="4">Target Concentrations Vitamin B12 (pg/mL)</td><td>Level A: 45</td><td>Level A: 0</td></tr><tr><td>Level B: 200</td><td>Level B: 200</td></tr><tr><td>Level C: 500</td><td>Level C: 500</td></tr><tr><td>Level D: 1000</td><td>Level D: 1000</td></tr><tr><td></td><td>Level E: 2200</td><td>Level E: 2200</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

• Clinical and Laboratory Standards Institute (CLSI) Guideline EP5-A2: Evaluation of Precision Performance of Quantitative Measurement Methods

CLSI Guideline EP 17-A: Protocols for Determination of Limits of Detection and Limits of Quantitation

CLSI Guideline EP6-A: Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach

CLSI Guideline EP9-A2: Method Comparison and Bias Estimation Using Patient Samples

· CLSI Guideline EP7-A2: Interference Testing in Clinical Chemistry

CLSI Guideline C28-A2: How to Define and Determine Reference Intervals in the Clinical Laboratory

# L. Test Principle:

The LOCI Vitamin B12 method is a homogeneous, competitive chemiluminescent immunoassay based on LOCI technology. LOCI reagents include two synthetic bead reagents and biotinylated intrinsic factor (IF). The first bead reagent (Chemibead) is coated with a B12 derivative and contains a chemiluminescent dye. The second bead reagent (Sensibead) is coated with streptavidin and contains photosensitive dye. The patient sample is pretreated with sodium hydroxide (NaOH) and dithioerythritol (DTE) to release the serum B12 from its carrier proteins. Potassium cyanide (KCN) is added to convert all the forms of B12 into a single, cyanocobalamin form, and dicyanocobinamide is added to keep the B12 from rebinding with the carrier proteins. After the sample pretreatment, the biotinylated IF and chemibead reagents are added sequentially to the reaction vessel. Vitamin B12 from the sample competes with the B12-chemibead for a limited amount of biotinylated IF. Sensibead reagent is then added and binds to the biotin to form bead pair immunocomplexes.

Illumination of the complex at $6 8 0 \mathrm { n m }$ generates singlet oxygen from the Sensibeads which diffuses to the Chemibeads triggering a chemiluminescent reaction. The resulting signal is measured at $6 1 2 \mathrm { n m }$ and is an inverse function of the concentration of vitamin B12 in the sample.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

# a. Precision/Reproducibility:

The precision study was designed based on the CLSI document EP5-A2. Bio-Rad Liquichek Control materials, patient serum and lithium heparin plasma pools were used for the precision study. One lot of reagent and one instrument was used (Vista 1500 analyzer). For each sample, a single test from two independent cups was analyzed twice per day for 20 days. The within-run and within-lab standard deviations were calculated by the analysis of variance method.

The results are summarized below.

<table><tr><td rowspan=2 colspan=1>Samples</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(pg/mL)</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Within-Lab</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Serumpool 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>238</td><td rowspan=1 colspan=1>8.4</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>18.0</td><td rowspan=1 colspan=1>7.6</td></tr><tr><td rowspan=1 colspan=1>Plasma pool 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>365</td><td rowspan=1 colspan=1>8.9</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>12.3</td><td rowspan=1 colspan=1>3.4</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1007</td><td rowspan=1 colspan=1>14.4</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>21.0</td><td rowspan=1 colspan=1>2.1</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1716</td><td rowspan=1 colspan=1>20.6</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>32.7</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1>Low control</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>275</td><td rowspan=1 colspan=1>11.0</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>19.2</td><td rowspan=1 colspan=1>7.0</td></tr><tr><td rowspan=1 colspan=1>Medium control</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>518</td><td rowspan=1 colspan=1>8.2</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>20.3</td><td rowspan=1 colspan=1>3.9</td></tr><tr><td rowspan=1 colspan=1>High control</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>682</td><td rowspan=1 colspan=1>16.3</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>20.1</td><td rowspan=1 colspan=1>3.0</td></tr></table>

# $b$ . Linearity/assay reportable range:

A linearity study was performed to support the measuring range claim. A native high and a native low serum pool were combined in different ratios to produce 9 dilution pools covering the intended assay range. All 9 pools were measured 5 times on a single instrument (Vista 1500 analyzer). Sample ranges tested were between 22 to $2 1 0 9 \ : \mathrm { p g / m L }$ . The linear regression was determined by plotting the observed values against the expected values and generated the following equation: $\mathbf { y } = 0 . 9 9 \mathbf { x } + 0 . 2 2$ . A summary of the linearity results are listed in the table below.

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>% HighSample</td><td rowspan=1 colspan=1>Expectedpg/mL</td><td rowspan=1 colspan=1>MeanObservedvalue, n=5pg/mL</td><td rowspan=1 colspan=1>Linear Fit</td><td rowspan=1 colspan=1>Difference vs.Linear fit%</td></tr><tr><td rowspan=1 colspan=1>LV1</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>2337</td><td rowspan=1 colspan=1>2109</td><td rowspan=1 colspan=1>2276</td><td rowspan=1 colspan=1>-7.3%</td></tr><tr><td rowspan=1 colspan=1>LV2</td><td rowspan=1 colspan=1>82.5%</td><td rowspan=1 colspan=1>1898</td><td rowspan=1 colspan=1>1958</td><td rowspan=1 colspan=1>1881</td><td rowspan=1 colspan=1>4.1%</td></tr><tr><td rowspan=1 colspan=1>LV3</td><td rowspan=1 colspan=1>75.0%</td><td rowspan=1 colspan=1>1727</td><td rowspan=1 colspan=1>1695</td><td rowspan=1 colspan=1>1712</td><td rowspan=1 colspan=1>-1.0%</td></tr><tr><td rowspan=1 colspan=1>LV4</td><td rowspan=1 colspan=1>62.5%</td><td rowspan=1 colspan=1>1443</td><td rowspan=1 colspan=1>1436</td><td rowspan=1 colspan=1>1431</td><td rowspan=1 colspan=1>0.4%</td></tr><tr><td rowspan=1 colspan=1>LV5</td><td rowspan=1 colspan=1>50.0%</td><td rowspan=1 colspan=1>1159</td><td rowspan=1 colspan=1>1169</td><td rowspan=1 colspan=1>1149</td><td rowspan=1 colspan=1>1.7%</td></tr><tr><td rowspan=1 colspan=1>LV6</td><td rowspan=1 colspan=1>37.5%</td><td rowspan=1 colspan=1>875</td><td rowspan=1 colspan=1>875</td><td rowspan=1 colspan=1>867</td><td rowspan=1 colspan=1>0.9%</td></tr><tr><td rowspan=1 colspan=1>LV7</td><td rowspan=1 colspan=1>25.0%</td><td rowspan=1 colspan=1>591</td><td rowspan=1 colspan=1>586</td><td rowspan=1 colspan=1>586</td><td rowspan=1 colspan=1>0.1%</td></tr><tr><td rowspan=1 colspan=1>LV8</td><td rowspan=1 colspan=1>12.5%</td><td rowspan=1 colspan=1>306</td><td rowspan=1 colspan=1>308</td><td rowspan=1 colspan=1>304</td><td rowspan=1 colspan=1>1.3%</td></tr><tr><td rowspan=1 colspan=1>LV9</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>-0.1%</td></tr></table>

The linearity study supports the sponsor’s claim that the B12 assay has a reportable range of 60 to $2 0 0 0 \mathrm { p g / m L }$ .

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Traceability: The Dimension Vista B12 calibrators are traceable to USP grade vitamin B12 by gravimetric method. Ferritin is traceable to the WHO Standard for ferritin, $3 ^ { \mathrm { r d } }$ IS 94/572. Folate is traceable to the US Pharmacopeia Grade folic acid.

# Value assignment:

Vitamin B12: The anchor pool consists of 5 levels of VB12 in human serum based material. The assigned value of the anchor pool is based on the Roche Elecsys. To provide stability, a large reserve of anchor pool is stored frozen at $7 0 \pm 2 0 \ ^ { \circ } \mathrm { C }$ . Aliquots of the anchor pool are used to produce the master pools. Values are assigned to each lot of calibrator from the master pool using the Dimension Vista System. The master pool is a frozen liquid, five-level material. The master pool has the same composition as the calibrator which is held in reserve. The value assignment is derived from 9 runs $\mathrm { \Pi } _ { \mathrm { n } } { = } 5$ replicates) on 3 instruments using 3 reagents lots.

Folate: The anchor pool consists of 6 levels of Folate in human serum base material. The assigned value of the anchor pool is based on the ADVIA Centaur folate method at 3 external sites. To provide stability, a large reserve of anchor pool is stored frozen at $- 7 0 \pm 2 0 \ ^ { \circ } \mathrm { C }$ . Aliquots of the anchor pool are used to produce the master pools. Values are assigned to each lot of calibrator from the master pool using the Dimension Vista System. The master pool is a frozen liquid, five-level material. The master pool has the same composition as the calibrator which is held in reserve. The value assignment is derived from 9 runs $\mathrm { \Pi } _ { \mathrm { n } } { = } 5$ replicates) on 3 instruments using 3 reagents lots.

Ferritin: The anchor pool is based on WHO Standard for Ferritin $3 ^ { \mathrm { r d } }$ IS 94/572. Nine levels of ferritin are gravimetrically prepared. To provide stability, a large reserve of anchor pool is stored frozen at $- 7 0 \pm 2 0 \ ^ { \circ } \mathrm { C }$ . Aliquots of the anchor pool are used to produce the master pools. Values are assigned to each lot of calibrator from the master pool using the Dimension Vista System. The master pool is a frozen liquid, five-level material. The master pool has the same composition as the calibrator which is held in reserve. The value assignment is derived from 9 runs $\mathrm { ( n } { = } 5$ replicates) on 3 instruments using 3 reagents lots.

Stability of calibrators (folate, ferritin, and vitamin B12): Real–time stability protocols and acceptance criteria for shelf-life and in-use (open vial) stability were reviewed and found to be acceptable. Unopened thawed calibrator material is stable for 30 days at $2 { - } 8 \ ^ { \circ } \mathrm { C }$ . Once the stopper of the vial is punctured, assigned values are stable for 7 days when stored aboard the instrument. Once the cap is removed, assigned values are stable for 30 days when recapped immediately and stored at 2-8 $^ { \circ } \mathrm { C }$ .

# d. Detection limit:

The Limit of Blank (LoB) and Limit of Detection (LoD) for the VB12 method was determined based on the CLSI document EP17-A. Blank samples $( \mathrm { N } { = } 5 )$ were prepared using five lots of HEPES buffer to determine the LoB. Low analyte samples $( \mathrm { N } { = } 5 )$ were serum samples with low endogenous B12 ranging from 32 to $6 2 ~ \mathrm { p g / m L }$ to determine the LoD. Each sample was tested in duplicate, using two lots of reagents once a day over 3 days for a total of 12 results per sample (total $\mathrm { N } { = } 6 0$ ).

The limit of quantification (LoQ) is defined as the lowest analyte concentration that can be reproducibly measured with a total CV of $\leq 2 0 \%$ . Seven serum pools with low endogenous B12 levels ranging from 40 to $1 8 0 ~ \mathrm { p g / m L }$ were analyzed in duplicate, once a day for twenty days for a total of 40 results per sample.

The results are summarized in the below table.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>LoB</td><td rowspan=1 colspan=1>LoD</td><td rowspan=1 colspan=1>LoQ</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>18.0 pg/mL</td><td rowspan=1 colspan=1>28.0 pg/mL</td><td rowspan=1 colspan=1>52 pg/mL</td></tr></table>

The B12 assay has a measuring range of $6 0 \mathrm { - } 2 0 0 0 \mathrm { p g / m L }$ .

# e. Analytical specificity:

Interference: Interference testing was performed according to CLSI EP7-A2 guideline to determine the effect of various endogenous and exogenous substances on the Dimension Vista VB12 assay. For all interferents, except rheumatoid factors (RF), the percent bias was determined by testing a control sample without the interferent and comparing it to the value obtained from a test sample to which the

potential interferent had been added. For RF interference, a human serum sample with a RF level of $5 0 0 \ \mathrm { I U / m L }$ and a normal human serum sample were spiked with the same level of vitamin B12. Interferents were tested at two levels of vitamin B12, approximately $2 0 0 \ : \mathrm { p g / m L }$ and $1 0 0 0 \mathrm { p g / m L }$ . For each spiked sample, the $\%$ recovery was determined. The acceptance criteria of $\leq 1 0 \%$ relative deviation from the control were met for all interferents tested except Dextran 40 and Hemoglobin. Dextran 40 and Hemoglobin with $a > 1 0 \%$ bias were repeated at lower concentrations to determine a level where the bias became less than $10 \%$ . The sponsor states in the Instructions for Use labeling that Dextran 40 at $6 \mathrm { g / d L }$ decreases VB12 by $- 1 1 . 9 \%$ at $2 0 0 { \mathrm { p g / d L } }$ and that hemoglobin at $5 0 0 \mathrm { m g / d L }$ increases VB12 results by $1 9 . 8 \%$ at 200 $\mathrm { p g / d L }$ .

The hemolysis, icterus, and lipemia (HIL) limits where the interference bias does not exceed $10 \%$ were determined to be as follows:

· Bilirubin $\begin{array} { l } { \leq 6 0 \mathrm { m g / d L } } \\ { \leq 3 0 0 \mathrm { m g / d L } } \\ { \leq 3 0 0 0 \mathrm { m g / d L } } \end{array}$   
· Hemoglobin   
Triglycerides

The sponsor states in the Instructions for Use labeling to avoid using hemolyzed samples.

Cross reactivity: Cross reactivity of cobinamide with the Dimension Vista VB12 antibody was challenged at a concentration of $2 0 0 ~ \mathrm { { n g / m L } }$ . Cobinamide was added to a serum pool with a vitamin B12 level of $2 0 0 \ : \mathrm { p g / m L }$ . The cross-reactivity was determined by testing a control sample $( \mathrm { n } { = } 5 )$ ) without cobinamide and comparing it to the value obtained from a test sample $( \mathtt { n } ^ { = 5 } )$ to which cobinamide $( 2 0 0 ~ \mathrm { n g / m L } )$ had been added. The percent cross-reactivity was calculated and the sponsor concluded that there is no cross-reactivity $( \leq 1 \% )$ with cobinamide.

# Intrinsic Factor Blocking Antibody (IFBA) interference:

An IFBA interference study was performed to assess the interference effects of IFBA on VB12 measurements. Patient samples with both positive and negative IFBA were assayed by both the candidate and the predicate device (Roche Elecsys). The VB12 concentration of the samples ranged from $6 0 { - } 2 0 0 0 \ \mathrm { p g / m L }$ . The sponsor concludes that test performed demonstrates that the Dimension Vista Vitamin B12 assay effectively mitigates the interference of IFBA. Results from the candidate device (Y) were plot against the predicate device (X) and a linear regression analysis was performed. The table below summarizes the IFBA interference study results:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>IFBA negative samples</td><td rowspan=1 colspan=1>IFBA positive samples</td></tr><tr><td rowspan=1 colspan=1>r2}$</td><td rowspan=1 colspan=1>0.971</td><td rowspan=1 colspan=1>0.990</td></tr><tr><td rowspan=1 colspan=1>slope</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>1.01</td></tr><tr><td rowspan=1 colspan=1>intercept</td><td rowspan=1 colspan=1>-2.0</td><td rowspan=1 colspan=1>-2.0</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>78</td><td rowspan=1 colspan=1>79</td></tr></table>

The sponsor included the following limitation in their labeling:

Intrinsic blocking antibodies are present in approximately half of pernicious anemia patients. There is a low frequency possibility that these antibodies may not be completely inactivated during the reaction pretreatment step. If test results are in conflict with the clinical diagnosis, the sample can be tested for intrinsic factor blocking antibodies.

f. Assay cut-off: Not applicable.

2. Comparison studies:

a. Method comparison with predicate device:

The Dimension Vista VB12 assay was compared to the Vitamin B12 assay on the Roche Elecsys System by evaluating one hundred sixty-two native serum samples across the claimed measuring range. The samples ranged from 69 to $1 8 2 9 \mathrm { p g / m L }$ on the Roche Elecsys, and 68 to $1 9 6 3 ~ \mathrm { p g / m L }$ on the Dimension Vista. The sample set included 32 samples with known Intrinsic Factor Binding Antibody (IFBA) titers ranging from 7 to $1 3 3 . 8 5 \mathrm { U } / \mathrm { m L }$ .

Passing-Bablok regression analysis of the results yielded the following:

<table><tr><td rowspan=1 colspan=1>Regression</td><td rowspan=1 colspan=1>Bias</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Constant (Y-intercept)</td><td rowspan=1 colspan=1>-7.64</td><td rowspan=1 colspan=1>-17 to -0.48</td></tr><tr><td rowspan=1 colspan=1>Proportional (X-slope)</td><td rowspan=1 colspan=1>0.985</td><td rowspan=1 colspan=1>0.965 to 1.004</td></tr></table>

The correlation coefficient for this data set (R) is 0.993

b. Matrix comparison:

Serum, EDTA plasma, lithium heparin plasma and sodium heparin plasma are the recommended specimen types for the Dimension Vista VB12 assay. Seventy-one matched sets of serum, lithium heparin, sodium heparin, and EDTA plasma freshly drawn from healthy donors were tested on the Dimension Vista VB12 assay. Sixty-four sets were native samples with serum B12 levels ranging from 125 to $1 1 7 4 ~ \mathrm { p g / m L }$ . Seven sets were spiked with B12 in equal amounts to all sample types to cover ranges from 1116 to $1 8 2 1 ~ \mathrm { p g / m L }$ . All samples were tested $( \mathrm { n } { = } 2 )$ with the VB12 assay on the Dimension Vista 1500 System. The first replicate of the results were used for analyzing the linear regression analysis.

Ordinary least squares linear regression was used to fit the mean B12 results of each of the plasma types against serum. The data and regression analysis is summarized below:

Sample Description

<table><tr><td rowspan=1 colspan=1>Vitamin B12</td><td rowspan=1 colspan=1>EDTA Plasma</td><td rowspan=1 colspan=1>Li-Hep Plasma</td><td rowspan=1 colspan=1>Na-HepPlasma</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>71</td></tr><tr><td rowspan=1 colspan=1>Min (pg/mL)</td><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>116</td><td rowspan=1 colspan=1>126</td><td rowspan=1 colspan=1>125</td></tr><tr><td rowspan=1 colspan=1>Max (pg/mL)</td><td rowspan=1 colspan=1>1836</td><td rowspan=1 colspan=1>1853</td><td rowspan=1 colspan=1>1788</td><td rowspan=1 colspan=1>1821</td></tr></table>

Least Squares Regression Analysis (Plasma vs. Serum)   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>EDTA Plasma</td><td rowspan=1 colspan=1>Li-Hep Plasma</td><td rowspan=1 colspan=1>Na-HepPlasma</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>0.991</td><td rowspan=1 colspan=1>0.998</td><td rowspan=1 colspan=1>0.991</td></tr><tr><td rowspan=1 colspan=1>Y-Intercept</td><td rowspan=1 colspan=1>-11.2</td><td rowspan=1 colspan=1>-4.9</td><td rowspan=1 colspan=1>-2.7</td></tr><tr><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>0.998</td><td rowspan=1 colspan=1>0.999</td><td rowspan=1 colspan=1>0.999</td></tr></table>

3. Clinical studies:

a. Clinical Sensitivity: Not applicable.   
$b$ . Clinical specificity: Not applicable.   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4. Clinical cut-off: Not applicable.

5. Expected values/Reference range:

Reference intervals were established for the Dimension Vista VB12 assay according to C28-A3. Samples from apparently healthy adults (age 20-64, $60 \%$ male and $40 \%$ female) were collected in the US $( \mathrm { N } { = } 2 0 0 )$ ) and in the European Union $\scriptstyle ( \mathrm { N } = 1 9 9$ ). The results were analyzed non-parametrically to determine the central $9 5 \%$ region for each population and a reference interval for each population was determined. The results are summarized as follows:

United States Population Reference Range: $1 9 3 { \mathrm { - } } 9 8 6 \ \mathrm { p g / m L }$ $( \mathrm { n } { = } 2 0 0 )$ )

European Union Population Reference Range: $1 8 2 { - } 6 2 5 \ \mathrm { p g / m L }$ $\scriptstyle ( \mathrm { n = 1 9 9 }$ )

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.